A randomized phase 3 study of abemaciclib versus erlotinib in previously treated patients with stage IV NSCLC with KRAS mutation: JUNIPER
Congress and symposium participations > Congress · 2018
Authors: Tuncay GÖKSEL
2018-2018, A randomized phase 3 study of abemaciclib versus erlotinib in previously treated patients with stage IV NSCLC with KRAS mutation: JUNIPER, Congress, Attendee, United States Of America, Colorado